OmniAb (OABI) Long-Term Investments (2021 - 2022)
OmniAb (OABI) reported Long-Term Investments of $237.2 million for Q3 2022, up 0.61% year-over-year from $235.8 million in Q3 2021, and little changed quarter-over-quarter from $236.1 million in Q2 2022.
OmniAb (OABI) Long-Term Investments (2021 - 2022) Analysis & Trends
OmniAb (OABI) has 2 years of Long-Term Investments data on file, last reported at $237.2 million in Q3 2022.
- Long-Term Investments for Q3 2022 came in at $237.2 million, up 0.61% year-over-year; the trailing twelve-month figure through Sep 2022 was $237.2 million (up 0.61% YoY), and the FY2021 annual result was $235.8 million, changed N/A from the prior year.
- Long-Term Investments was little changed at $237.2 million in Q3 2022 per OABI's latest filing, from $236.1 million in the prior quarter.
- Over five years, Long-Term Investments peaked at $237.2 million in Q3 2022 and troughed at $235.8 million in Q3 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 5.17 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 5.75 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | OmniAb | 294.96 Mn | 252.00 Mn | 14.41 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2022 | 237.19 Mn |
| Jun 30, 2022 | 236.10 Mn |
| Mar 31, 2022 | 235.80 Mn |
| Dec 31, 2021 | 235.75 Mn |
| Sep 30, 2021 | 235.75 Mn |